Headline;Month;Day
Morning Agenda: Tenants Struggle in Win-Win Contracts for Landlords;8;22
Tax-Avoiding Mergers Find Champion in U.S. Chamber of Commerce;8;4
Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion;5;16
Pfizer Needs Clearer Goals;5;5
Pfizer Blocks the Use of Its Drugs in Executions;5;13
Free Pfizer! Why Inversions Are Good for the U.S.;4;7
Pfizer Chief on Drug Pricing;1;11
Allergan Says U.S. Targeted Pfizer Deal;4;6
Finger-Pointing Abounds in Failed Pfizer Deal;4;6
Pfizer Faces Limited Options After Its Dead Deal With Allergan;4;6
Pfizer Faces Limited Options After Its Dead Deal With Allergan;4;6
Pfizer and Allergan Are Said to End Merger as Tax Rules Tighten;4;5
Carl Icahn Takes Stake in Allergan;5;31
Pfizer’s Eager to Go, but the Market Has Doubts;3;12
Pfizer and Allergan Advisers Lose Out on $200 Million in Fees;4;6
Morning Agenda: Pfizer Said to Call Off Merger With Allergan;4;6
Plan to Curb Tax-Inversion Deals Could Go Too Far;7;7
Your Friday Evening Briefing: Donald Trump, Hezbollah, Pfizer;5;13
Your Wednesday Evening Briefing: Panama Papers, Pfizer, Donald Trump;4;6
Morning Agenda: Election Years Are Steeped in Markets’ Least Favorite Thing, Uncertainty;5;17
Change Is in the Air for Pharmaceutical Mergers;5;10
Hedge Funds Look for Hard Hats in a Year of Collapsing Mergers;5;12
Morning Agenda:  Donald Trump Names Hedge Fund Manager as National Finance Chairman;5;6
Morning Agenda: Pulte Founder Pitted Against the Board;5;4
The Winds From Washington Chill Wall Street’s Deal Making;4;14
A Corporate Tax Dodge Gets Harder;4;6
Lessons in a Busy Week of Deal Busting;4;7
Megamergers Face Deterrents in the United States;4;7
U.S. Moves to Thwart Use of Foreign Inversions as Tax Dodge;4;5
Morning Agenda: U.S. Moves to Restrict Foreign Deals Intended to Avoid Taxes;4;5
Morning Agenda: Megamergers Face Increasing Challenges in U.S.;4;7
On Inversions, the Treasury Department Drops the Gloves;4;5
Morning Agenda: Start-Up Investors Are Not Waiting for Growth;3;14
Christopher Pierce, Jonathan Pollock;10;9
A Progressive Way to End Corporate Taxes;1;12
Trump on Cruz's Eligibility;1;26
Corporate Inversions Aren’t the Half of It;2;10
The Corporate Tax Dodge Continues;1;30
Drug Companies to Try a Unified Front Against Cancer;1;11
Is ‘Generic Viagra’ Legitimate?;7;25
Allergan Earnings, the Mobile World Congress and Durable Goods Data;2;22
Sanofi Ends Marketing Deal With Developer of Inhaled Insulin;1;5
A Standout Year for Deals, in Volume and Complexity;1;3
An N.Y.U. Study Gone Wrong, and a Top Researcher Dismissed;6;27
A Tidal Wave of Corporate Migrants Seeking (Tax) Shelter;1;26
Johnson Controls and Tyco Can Take a Political Punch;1;25
Investors Sharpen Focus on Social and Environmental Risks to Stocks;12;15
Astrid Hugentobler, Jason Trost;2;28
Biden Names Leader for ‘Moonshot’ Cancer Campaign;3;18
Two Ranking Democrats to Offer Bill Aimed at Inversions;2;22
Alyssa Colbert, Gregory Barrett;6;5
Claire Hankin, Taylor Wray;8;14
Johnson & Johnson and Actelion Confirm Merger Talks Are Back On;12;21
Hope Yates, Manu Nathan;5;1
Hemophilia Patient or Drug Seller? Dual Role Creates Ethical Quandary;1;13
2 Lawyers Leaving Paul, Weiss to Form Boutique Firm;1;21
Just Send the Tax Bill to My Personal Irish Subsidiary;2;19
Justice Dept. Sues to Block Halliburton-Baker Hughes Merger;4;6
Health Care Companies See Scale as the Only Way to Compete;4;29
Alfred E. Mann, Pioneer in Medical Devices, Dies at 90;2;27
William Ackman Sets Out to Sell $800 Million in Shares of Zoetis;5;9
Centerview Partners Hires Jack Levy, Formerly of Goldman;2;24
Halliburton-Baker Hughes Breakup Is a Lesson in Hubris;5;2
Shakiness of Giant Deals Poses No Threat to 2015 Record;9;7
Jazz Pharmaceuticals to Buy Celator for $1.5 Billion;5;31
Fertilizer Deal Called Off Over New Tax Inversion Rules;5;23
Hostile Takeover Battle Can Weaken a Company’s Defenses;9;13
Morning Agenda: Bank Rule Distorting Performance Is Repealed;1;6
Johnson & Johnson Is Urged to Slim Down;6;2
Investors Doubt Proposed Deals by Aetna and Anthem;7;8
Theresa May’s Vision of a Radical British Conservatism;7;19
F.D.A. Urges Caution on Yeast Infection Drug During Pregnancy;4;27
William Ackman’s Pershing Square Takes a Stake in Chipotle;9;6
Morning Agenda: Oil Prices Volatile While Chinese Markets Sink;1;4
Brand-Name Drug Makers Wary of Letting Generic Rival Join Their Club;7;1
Ireland, Home to U.S. ‘Inversions,’ Sees Huge Growth in G.D.P.;7;12
To Fight ‘Superbugs,’ Drug Makers Call for Incentives to Develop Antibiotics;1;21
A Stranded $2 Trillion Overseas Stash Gets Closer to Coming Home;11;4
Canadian Pacific Ends Bid for Norfolk Southern;4;11
Top Lobbyist for Drug Makers Threads a Thicket of Outrage;2;26
Slowdown in Merger Deals Attributed to Political Uncertainty;7;1
Top Lobbyist for Drug Makers Threads a Thicket of Outrage;2;26
Review: In ‘Career Suicide,’ Laughing When It Hurts;10;14
Future of Big Mergers Under Trump? Like Much Else, It’s Unclear;11;10
The U.S. Is Standing in the Way of Cheaper Drugs for the Poor;10;27
Your Monday Briefing: Donald Trump, Hillary Clinton, Manchester United;5;16
Wall Street Bonuses Are Expected to Sink for 3rd Straight Year;11;7
Ackman’s Hedge Fund Sells Off Big Stake in Canadian Pacific;8;3
Even Talking About Reducing Drug Prices Can Reduce Drug Prices;1;18
Morning Agenda: Yahoo’s Potential Bidders Frustrated Over Lack of Figures;4;15
Your Monday Evening Briefing: David Bowie, Golden Globes, Sean Penn;1;11
Strangers Help a Wheelchair Racer (and Find Out Later She’s a Gold Medalist);11;7
6 Hospitalized, One of Them Brain-Dead, After Drug Trial in France;1;15
Wall Street Bonuses Are Expected to Sink for 3rd Straight Year;11;7
Ackman’s Hedge Fund Sells Off Big Stake in Canadian Pacific;8;3
From Wall St. Bundlers to Bradley Cooper: Inside the State Dinner Guest Lists;3;10
Your Weekend Briefing: Masters Tournament, Bernie Sanders, Pope Francis;4;10
Buybacks by Companies Like Apple May Signal Danger, Not Growth;6;23
Your Wednesday Briefing: Ted Cruz, Bernie Sanders, Panama;4;6
U.S. Sues to Block Anthem-Cigna and Aetna-Humana Mergers;7;21
From Wall St. Bundlers to Bradley Cooper: Inside the State Dinner Guest Lists;3;10
Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions;7;15
Turing Pharmaceuticals Accused of Retaliating for Sex Assault Complaint;8;23
Study Shows Promise for Expensive Cholesterol Drugs, but They Are Still Hard to Obtain;11;15
European Privacy Regulators Want Details on ‘Safe Harbor’ Data Deal;2;3
Justice Dept. Will Seek to Block 2 Health Insurance Mergers;7;19
Volkswagen Case Gives Judge, Onetime Aspiring Actor, Role of a Lifetime;4;19
Mylan Tries Again to Quell Pricing Outrage by Offering Generic EpiPen;8;29
Wary Drug Makers Move to Fend Off Further Attacks Under Donald Trump;12;9
Mylan Raised EpiPen’s Price Before the Expected Arrival of a Generic;8;25
Tyco Merger Will Shift Johnson Controls’ Tax Liability Overseas;1;25
Carnegie Hill: A Quiet Enclave Bordering the Park;11;9
A Treasury Secretary at the Center of Obama’s Most Pressing Policies;4;8
U.S. and Europe in ‘Safe Harbor’ Data Deal, but Legal Fight May Await;2;2
Labour Party in Britain Faces Its Worst Crisis in Decades;7;28
For Indian Start-Ups, Tenacity Beats High Tech;4;12
The Lower East Side, Where Gritty Meets Trendy;3;30
Centerview Benefits From Wall St.’s Pivot to Smaller Banks;1;5
General Mills and 7-Eleven Join the Venture Capital Crowd;4;18
Morning Agenda: Herbalife vs. Activist: Just Maybe He’s Right;8;2
Lives and Profits in the Balance: The High Stakes of Medical Patents;12;12
Waste in Cancer Drugs Costs $3 Billion a Year, a Study Says;3;1
Europe’s Top Digital-Privacy Watchdog Zeros In on U.S. Tech Giants;1;24
Trump and Congress Both Want Tax Cuts. The Question Is Which Ones.;11;12
Taxing Google and Other U.S. Giants Is Dividing Europe;1;28
Vanguard, a Champion of Low Fees, Faces a Peculiar Tax Challenge;2;6
A Lobbyist Wrote the Bill. Will the Tobacco Industry Win Its E-Cigarette Fight?;9;2
‘President Trump?’ Here’s How He Says It Would Look;5;4
Morning Agenda: A Tidal Wave of Corporate Migrants Seeking Tax Shelters;1;26
Morning Agenda: Why Judge Removed MetLife’s ‘Too Big to Fail’ Label;4;8
For the Active and Over 50;11;22
Morning Agenda: The Struggles of Today’s Sumner Redstone;6;1
Morning Agenda: Warren Buffett Talks of Sharing the Wealth;5;3
Morning Agenda: Heresy on Wall Street;2;2
Morning Agenda:  Banking in the Time of ‘Brexit’;6;29
What Happened to North Carolina?;10;7
Political Substance Abuse: Donald Trump in Florida;3;17
At a Loss for Meds, Venezuela’s Mentally Ill Spiral Downward;10;1
After ‘The Biggest Loser,’ Their Bodies Fought to Regain Weight;5;2
Drug Giant Faced a Reckoning as China Took Aim at Bribery;11;1
Drug Giant Faced a Reckoning as China Took Aim at Bribery;11;1
Could Ancient Remedies Hold the Answer to the Looming Antibiotics Crisis?;9;14
The Faces of American Power, Nearly as White as the Oscar Nominees;2;26
Meet the Highest-Paid C.E.O.s in 2015;5;27
Transcript: Donald Trump Expounds on His Foreign Policy Views;3;26
Transcript of the Republican Presidential Debate;2;7
Corporate Tactics to Avoid Taxes;4;13
High Vaccine Prices;7;4
